Biohaven Files 8-K for Regulation FD Disclosure

Ticker: BHVN · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1935979

Biohaven Ltd. 8-K Filing Summary
FieldDetail
CompanyBiohaven Ltd. (BHVN)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, disclosure

TL;DR

**Biohaven just dropped an 8-K for Regulation FD; check for the actual news!**

AI Summary

Biohaven Ltd. filed an 8-K on January 8, 2024, primarily to disclose information under Regulation FD. This filing indicates that the company is providing information that was not previously public, likely to ensure fair and broad dissemination to all investors. For shareholders, this means Biohaven is being transparent, but the filing itself doesn't detail the specific information disclosed, so investors should look for a related press release or announcement to understand the substance of the disclosure.

Why It Matters

This filing signals that Biohaven Ltd. has released material non-public information, which could impact its stock price depending on the nature of the disclosure. Investors need to find the actual content of the Regulation FD disclosure to assess its implications.

Risk Assessment

Risk Level: low — The filing itself is a procedural disclosure under Regulation FD and does not inherently carry high risk, though the content of the undisclosed information could be significant.

Analyst Insight

Investors should immediately look for a separate press release or announcement from Biohaven Ltd. that details the specific information disclosed under Regulation FD to understand its potential impact on the company and its stock.

Key Players & Entities

  • Biohaven Ltd. (company) — the registrant filing the 8-K
  • New York Stock Exchange (company) — where Biohaven's Common Shares are registered
  • BHVN (company) — trading symbol for Biohaven Ltd.

FAQ

What is the primary purpose of Biohaven Ltd.'s 8-K filing on January 8, 2024?

The primary purpose of Biohaven Ltd.'s 8-K filing on January 8, 2024, is for a Regulation FD Disclosure, as indicated in the 'ITEM INFORMATION: Regulation FD Disclosure' section of the filing.

What is Biohaven Ltd.'s trading symbol and on which exchange are its common shares registered?

Biohaven Ltd.'s trading symbol is BHVN, and its Common Shares, with no par value, are registered on the New York Stock Exchange, as stated under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 8, 2024, as specified under 'Date of Report (Date of earliest event reported): January 8, 2024'.

Where is Biohaven Ltd.'s principal executive office located?

Biohaven Ltd.'s principal executive office is located at c/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510, according to the filing.

Is Biohaven Ltd. considered an emerging growth company according to this filing?

No, Biohaven Ltd. is not indicated as an emerging growth company, as the checkbox for 'Emerging growth company' is not marked in the filing.

Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-01-08 07:30:54

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On January 8, 2024, Biohaven Ltd. will be making an investor presentation (the "Presentation"). A copy of the Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Investor Presentation, dated January 2024 104 The cover page of this Current Report on Form 8-K formatted as Inline XBRL. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 Biohaven Ltd. By: /s/ Matthew Buten Matthew Buten Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.